• US lawmakers to introduce new bills to slash prescription drug prices

  US Senator Bernie Sanders and Representative Elijah Cummings have announced plans to introduce three new...
  Read More...

• NICE declines to endorse Novartis’ pricey migraine drug Aimovig

  National Institute for Health and Care Excellence (NICE) in the UK has rejected Novartis’ migraine...
  Read More...

• Can BMS make a success of its Celgene acquisition?

  Pharmaceutical company Bristol-Myers Squibb has bought US biotech Celgene for $74bn as it seeks to...
  Read More...

• CANbridge Pharmaceuticals expands partnership with Wuxi Biologics

  China’s CANbridge Pharmaceuticals has expanded its alliance with WuXi Biologics for the discovery, development and...
  Read More...

• Smart speaker solution to patient care debuted at CES 2019

  With an ageing population, more people than ever are relying on carers, be it professionals...
  Read More...

• Tough enrolment criteria for Phase IIa trial of Allakos’s chronic urticaria drug

  Allakos’s Phase IIa AK002 trial in chronic spontaneous urticaria had challenging enrolment criteria, two investigators...
  Read More...

• AAPS 2018: entering a new era of ultra-pure synthetic cannabinoids

  As the US increases the state-approved production and supply of cannabis-derived pharmaceutical products, there are...
  Read More...

• Pfizer partners with CytoReason on immune system models for drug discovery

  Israeli-machine learning company CytoReason has announced it has signed a collaboration agreement with Pfizer in...
  Read More...

• Takeda completes $62bn Shire acquisition

  Japan-based Takeda Pharmaceutical has officially completed the acquisition of UK headquartered Shire for a total...
  Read More...

• NHS Long Term Plan: focus on R&D and digital innovation

  The UK Government has launched the NHS Long Term Plan laying out the health service's...
  Read More...